



3rd DVFA-Life Science Conference

Biosimilars

8 June 2010

DVFA Center, Frankfurt/Main

► **Symposium for Corporates, Investors, Financial Analysts and Life Science Experts**

Supported by



MAYER • BROWN

Media Partner

|transkript

BIO DEUTSCHLAND



Society of Investment Professionals in Germany

Biosimilars or “follow-on biologics” are new versions of biopharmaceuticals or biologic drugs, following patent expiry. Unlike generic drugs, biosimilars are similar, but not identical copies of the original drug. Interest in the biosimilar-market is rapidly growing among investors and companies, fueled by upcoming patent expirations for many biological drugs, thirteen product approvals in Europe and the evolving regulatory pathway for the US. Analysts project already a US\$10bn market by 2015.

Biosimilars

The conference will cover key scientific topics, regulatory pathways and commercial issues of the biosimilar market. Key players will point out their view on the market potential and explain their strategic plans. This will enable conference attendees to evaluate the opportunities and hurdles of this new market segment.

Two panel sessions will feature in depth discussions. The first panel will discuss relevant topics such as cost savings for health insurers, counter strategies from innovator companies and clinical, commercial and safety issues such as immunogenicity, comparability and interchangeability. The second panel will discuss capital market relevant topics, such as short and longterm growth strategies, market potential of the biosimilar market, how to deal with costs for clinical development and manufacturing issues, pricing of biosimilars compared to original drugs and valuation of biosimilar companies.

- ▶ **A Symposium for:**
 - Corporates
 - Investors
 - Financial Analysts
 - Life Science Experts

- ▶ **Conference Language:**
 - English

Symposium

Tuesday, 8 June 2010

- 08:45 am ▶ **Check-in**
- 09:00 am ▶ **Welcome**
Ralf Frank, Managing Director, DVFA GmbH
Dr. Christa Bähr, DZ BANK & Chairwoman DVFA Committee Life Science
- 09:10 am ▶ **Origins and future of the biosimilars industry**
Dr. Ralf Emmerich, Managing Consultant / Life Science, Capgemini Consulting
- 09:45 am ▶ **Biosimilars - Regulatory strategies and pathway in the EU and US**
Falk Ehmann, MD, PhD, European Medicines Agency (EMA)
- 10:20 am ▶ **“Epo-zeta - A case study“**
Dr. Michael Mack, Vorstand, BIOCEUTICALS Arzneimittel AG
- 10:50 am ▶ **Coffee Break**
- 11:10 am ▶ **Biosimilars - A sophisticated market with attractive growth potential**
Dr. Christopher Klein, Head Global Licensing Biopharmaceuticals, Sandoz International GmbH
- 11:45 am ▶ **Biosimilars - Legal, IP and transactional aspects**
Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP
Rechtsanwälte
- 12:15 pm ▶ **Impact of Biosimilars on the Pharmaceutical Industry**
Panel I
Falk Ehmann, MD, PhD, European Medicines Agency (EMA)
Ronny Gal, Sanford C. Bernstein & Co
Prof. Bertram Häussler, IGES Institut
Dr. Christopher Klein, Sandoz Biopharmaceuticals
Moderation: Dr. Ralf Emmerich, Capgemini Consulting
- 01:15 pm ▶ **Lunch**
- 02:15 pm ▶ **The biosimilars opportunity - Challenges and key success factors**
Frank Pieters, Senior Vice President Global Biogenerics, Teva Pharmaceutical Ind. Ltd.
- 02:50 pm ▶ **Mammalian cell lines for manufacturing of biosimilars**
Dr. Gertraud Unterrainer, CFO, ProBioGen AG
- 03:20 pm ▶ **Coffee Break**
- 03:35 pm ▶ **Biosimilars in an Individualized Therapeutics World - The Challenge in Oncology**
Dr. Rainer Wessel, Chief Business Officer & Spokesman, GANYMED Pharmaceuticals AG
- 04:10 pm ▶ **Biosimilars in the Capital Market**
Panel II
Stephan Gittermann, Partner, Mayer Brown LLP Rechtsanwälte
Paul Greenland, Hospira Inc.
Dr. Elmar Kraus, DZ BANK
Dr. Manfred Rüdiger, Partner, LSP – Life Sciences Partners
Dr. Rainer Wessel, GANYMED Pharmaceuticals AG
Moderation: Dr. Markus Manns, Union Investment Privatfonds GmbH
- 05:15 pm ▶ **Get Together**

Target Group

Target group for the symposium are experts from the life science sector.

Venue

DVFA Center
Mainzer Landstrasse 37-39
D-60329 Frankfurt am Main
Tel.: +49 (0) 69 24 24 94 08

DVFA – Society of Investment Professionals in Germany

DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently, DVFA has more than 1,100 individual members representing over 400 investment firms, banks, asset managers, consultants and counselling businesses. DVFA assures the credibility of the professionals and the integrity of the market by offering internationally recognised qualification programmes, by providing platforms for professional financial communication, and by effective self-regulation.

Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access to a pan-European network with more than 17,000 investment professionals in 26 nations. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is part of a worldwide network of more than 50,000 investment professionals.

DVFA Commission LifeScience - Members as of June 2010:

Sascha Alilovic, MorphoSys AG
Dr. Christa Bähr, CEFA, CFA, DZ BANK AG
Dr. Viola Bronsema, BIO Deutschland e.V.
Ines-Regina Buth, CBA, akampion
Dr. Ralf Emmerich, Capgemini Deutschland GmbH
Dr. Ricardo M. Gent, DIB Deutsche Industrievereinigung Biotechnologie
Andreas Heinrichs, Vontobel Securities AG
Dr. Rüdiger Herrmann, WilmerHale
Stefan Höfer, Deutsche Börse AG
Dr. Solveigh Karola Mähler, QIAGEN N.V.
Dr. med. Markus Manns, Union Investment Privatfonds GmbH
Dr. Markus Metzger, STADA Arzneimittel AG
Dr. Martin Schnee, CCrA, CBA, Schnee Research
Dr. Julia Schüler, CBA, BioRegion Rhein-Neckar-Dreieck e.V

DVFA GmbH

Stefanie Reuter
Financial Communication
Mainzer Landstrasse 47a
D-60329 Frankfurt am Main
Tel.: +49 (0) 69 26 48 48 102
Fax: +49 (0) 69 26 48 48 489
Mail: str@dvfa.de
Web: www.dvfa.de

Content: DVFA GmbH
Design: ReichDesign, Frankfurt
Photos: www.shutterstock.com

Subject to modifications. Copyright 2010 DVFA GmbH.